Celgene Corp (CELG)

127.34
0.31 0.24
NASDAQ : Health Care
Prev Close 127.65
Open 127.45
Day Low/High 127.20 / 128.35
52 Wk Low/High 92.98 / 137.54
Volume 425.09K
Avg Volume 3.96M
Exchange NASDAQ
Shares Outstanding 782.35M
Market Cap 99.81B
EPS 2.60
P/E Ratio 39.62
Div & Yield N.A. (N.A)

Latest News

Back to Basics in Biotech

Back to Basics in Biotech

Stop losses do not work in this part of the market.

Looking to Buy Some Celgene? Now's a Good Time

Looking to Buy Some Celgene? Now's a Good Time

CELG looks like it has a promising future, according to the charts.

(Graphic: Business Wire)

(Graphic: Business Wire)

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that IDHIFA ® (enasidenib) was granted approval from the U.

Here's Why I'm Valuing Value Over Growth

Here's Why I'm Valuing Value Over Growth

Multiples have become quite rich and dysfunction in Washington could end up biting the markets.

Celgene Corporation To Webcast At Upcoming Investor Conference

Celgene Corporation To Webcast At Upcoming Investor Conference

Celgene Corporation (NASDAQ:CELG) plans to present at an upcoming investor conference where Celgene management will provide an overview of the Company.

Nasdaq Tumbles as Tech Takes a Turn Lower

Nasdaq Tumbles as Tech Takes a Turn Lower

The Nasdaq tumbles and the S&P 500 slides. The Dow rises slightly.

Wall Street Trades at Records as Facebook Rallies

Wall Street Trades at Records as Facebook Rallies

Stocks are higher.

Stock Futures Power Higher on Earnings Beat From Facebook

Stock Futures Power Higher on Earnings Beat From Facebook

Stock futures are higher.

Celgene Reports Second Quarter 2017 Operating And Financial Results

Celgene Reports Second Quarter 2017 Operating And Financial Results

Celgene Corporation (NASDAQ:CELG) reported net product sales of $3,256 million for the second quarter of 2017, a 19 percent increase from the same period in 2016.

Facebook on Fire - 5 Things You Must Know Before the Market Opens Thursday

Facebook on Fire - 5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures point higher after Facebook shares jump.

Celgene Corporation Announces Settlement Of Civil Litigation

Celgene Corporation Announces Settlement Of Civil Litigation

Celgene Corporation (NASDAQ:CELG) today announced that it has reached a civil settlement with Relator Brown, the Department of Justice, 28 States, the District of Columbia, and the City of Chicago to resolve the previously...

Celgene Settles 'Whistle Blower' Lawsuit for $280 Million

Celgene Settles 'Whistle Blower' Lawsuit for $280 Million

Celgene had been accused of marketing off-label uses for two of its cancer treatments.

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Stock prices are either unfairly dragged down by competitors' earnings news or by Amazon's spread into more businesses, Cramer said.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

Cramer: Rotations Hit Companies That Don't Deserve It

Cramer: Rotations Hit Companies That Don't Deserve It

Case in point: Home Depot and Lowe's.

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Risk Happens Fast: Doug Kass

Risk Happens Fast: Doug Kass

What you need to know.

3 Red-Hot Biotech Stocks That Could Get Even Hotter

3 Red-Hot Biotech Stocks That Could Get Even Hotter

An analyst weighs in.

Summer Watch List: How Some Key Names Are Stacking Up

Here's what to focus on from these stocks in July.

What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers

What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers

The FDA has placed a clinical hold on three combination studies of Merck's Keytruda in multiple myeloma.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Celgene Enters PD1 Market with BeiGene Deal

Celgene Enters PD1 Market with BeiGene Deal

Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.

Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring

Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring

BeiGene and Impax Laboratories were among the biotech movers in premarket trading on July 6.

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration With BeiGene To Advance PD-1 Inhibitor Program For Solid Tumor Cancers

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration With BeiGene To Advance PD-1 Inhibitor Program For Solid Tumor Cancers

Celgene Corporation (NASDAQ:CELG) and BeiGene, Ltd. (NASDAQ:BGNE) entered into a strategic collaboration to develop and commercialize BeiGene's investigational anti-programmed cell death protein 1 (PD-1) inhibitor,...

Celgene Stock Will Continue to Rise on MS Drug's Success: Leerink

Celgene Stock Will Continue to Rise on MS Drug's Success: Leerink

Leerink analysts see Celgene continuing in an upward trend as its new multiple sclerosis drug ozanimod differentiates itself from a competitive field.

Celgene Corporation To Announce Second Quarter 2017 Results On July 27, 2017

Celgene Corporation To Announce Second Quarter 2017 Results On July 27, 2017

Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, July 27, 2017 at 9 a.